CA3206153A1 - Solid forms of a cdk2 inhibitor - Google Patents
Solid forms of a cdk2 inhibitorInfo
- Publication number
- CA3206153A1 CA3206153A1 CA3206153A CA3206153A CA3206153A1 CA 3206153 A1 CA3206153 A1 CA 3206153A1 CA 3206153 A CA3206153 A CA 3206153A CA 3206153 A CA3206153 A CA 3206153A CA 3206153 A1 CA3206153 A1 CA 3206153A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- ppm
- values
- crystalline
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cereal-Derived Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130530P | 2020-12-24 | 2020-12-24 | |
| US63/130,530 | 2020-12-24 | ||
| PCT/IB2021/062082 WO2022137106A1 (en) | 2020-12-24 | 2021-12-21 | Solid forms of a cdk2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206153A1 true CA3206153A1 (en) | 2022-06-30 |
Family
ID=79283019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206153A Pending CA3206153A1 (en) | 2020-12-24 | 2021-12-21 | Solid forms of a cdk2 inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240076287A1 (enExample) |
| EP (1) | EP4267563A1 (enExample) |
| JP (2) | JP2024503235A (enExample) |
| KR (1) | KR20230122100A (enExample) |
| CN (1) | CN116723837B (enExample) |
| AU (1) | AU2021404974B2 (enExample) |
| CA (1) | CA3206153A1 (enExample) |
| MX (1) | MX2023007699A (enExample) |
| TW (1) | TWI823213B (enExample) |
| WO (1) | WO2022137106A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| CN118679150A (zh) * | 2022-01-27 | 2024-09-20 | 益方生物科技(上海)股份有限公司 | Cdk2抑制剂及其制备方法和用途 |
| WO2024046443A1 (en) * | 2022-09-01 | 2024-03-07 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocyclic compounds as selective cdk inhibitors |
| WO2025191482A1 (en) | 2024-03-15 | 2025-09-18 | Pfizer Inc. | Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| CA3128155C (en) * | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
-
2021
- 2021-12-21 MX MX2023007699A patent/MX2023007699A/es unknown
- 2021-12-21 WO PCT/IB2021/062082 patent/WO2022137106A1/en not_active Ceased
- 2021-12-21 AU AU2021404974A patent/AU2021404974B2/en active Active
- 2021-12-21 KR KR1020237024476A patent/KR20230122100A/ko active Pending
- 2021-12-21 CN CN202180086069.9A patent/CN116723837B/zh active Active
- 2021-12-21 EP EP21839682.8A patent/EP4267563A1/en active Pending
- 2021-12-21 CA CA3206153A patent/CA3206153A1/en active Pending
- 2021-12-21 US US18/268,959 patent/US20240076287A1/en active Pending
- 2021-12-21 JP JP2023537491A patent/JP2024503235A/ja active Pending
- 2021-12-23 TW TW110148386A patent/TWI823213B/zh active
-
2026
- 2026-04-16 JP JP2026067895A patent/JP2026123057A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007699A (es) | 2023-07-10 |
| KR20230122100A (ko) | 2023-08-22 |
| TW202233606A (zh) | 2022-09-01 |
| AU2021404974A1 (en) | 2023-07-06 |
| JP2026123057A (ja) | 2026-07-29 |
| AU2021404974B2 (en) | 2024-11-28 |
| WO2022137106A1 (en) | 2022-06-30 |
| TWI823213B (zh) | 2023-11-21 |
| JP2024503235A (ja) | 2024-01-25 |
| EP4267563A1 (en) | 2023-11-01 |
| CN116723837B (zh) | 2026-05-26 |
| CN116723837A (zh) | 2023-09-08 |
| AU2021404974A9 (en) | 2025-04-10 |
| US20240076287A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12570641B2 (en) | Solid forms of a CDK4 inhibitor | |
| AU2021404974B2 (en) | Solid forms of a cdk2 inhibitor | |
| US20240000783A1 (en) | Combination therapy | |
| CA3189632A1 (en) | Combination therapy | |
| CN117337293A (zh) | 固体形式的eif4e抑制剂 | |
| KR20240145475A (ko) | 고형 종양의 치료를 위한 유비퀴틴-특이적-프로세싱 프로테아제 1 (usp1) 억제제 | |
| JP2017529356A (ja) | チロシンキナーゼ阻害剤及びその塩の結晶形態 | |
| JP2025540560A (ja) | Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩 | |
| RU2850825C1 (ru) | Твердые формы ингибитора cdk2 | |
| CA3195063C (en) | Solid forms of the cdk4 inhibitor pf-07220060 | |
| RU2856216C1 (ru) | Твердые формы ингибитора cdk4 | |
| HK40096368A (en) | Solid forms of a cdk2 inhibitor | |
| BR112023004713B1 (pt) | Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica | |
| HK40087859A (en) | Solid forms of a cdk4 inhibitor | |
| HK40125945A (en) | Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor | |
| HK40131055A (en) | A pharmaceutical combination and use thereof | |
| BR112019019948A2 (pt) | derivado de 6-pirimidina-isoindol como inibidor de erk1/2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230621 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240820 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250207 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250527 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250619 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20251015 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251015 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251112 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260110 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260127 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260505 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260508 |